

# PRECEPTORSHIP PROGRAMME

## Gastric Cancer

Multidisciplinary management,  
standards of care, therapeutic targets  
and future perspectives

**VALENCIA**  
SPAIN

**6-7 OCTOBER 2017**

Co-Chairs    Andrés Cervantes, ES  
                  Florian Lordick, DE

# ESMO PRECEPTORSHIP PROGRAMME

## GASTRIC CANCER

Multidisciplinary management, standards of care,  
therapeutic targets and future perspectives

Valencia, Spain  
6-7 October 2017

**CO-CHAIRS:** Andrés Cervantes, Spain  
Florian Lordick, Germany

**SPEAKERS:** William Allum, United Kingdom  
Fabrice Caillol, France  
Fatima Carneiro, Portugal  
Karin Haustermans, Belgium  
Elizabeth Smyth, United Kingdom

### LEARNING OBJECTIVES

- To learn about the fundamentals of epidemiology, aetiology, pathogenesis, molecular events and ethnic patterns as contributing factors to heterogeneity in gastric cancer
- To understand the essentials in the diagnosis and multidisciplinary treatment of gastric cancer
- To learn about advances in the treatment and novel targets in gastric cancer

### ACCREDITATION

The programme of this event has been accredited with **9 ESMO-MORA category 1 points**.  
Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details, please refer to [esmo.org](http://esmo.org).

### ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from



### ORGANISATION AND CONTACTS

ESMO Head Office  
Education Department  
Via Luigi Taddei 4  
6962 Lugano - Viganello  
Switzerland  
Email: [courses@esmo.org](mailto:courses@esmo.org)  
[www.esmo.org](http://www.esmo.org)



## Friday, 6 October 2017

<b>09:00-09:10</b> <b>10'</b>	<b>Opening and welcome</b>	
5'	Welcome from ESMO	Andrés Cervantes, ES
5'	Objectives of the meeting	Andrés Cervantes, ES
<b>09:10-10:55</b> <b>105'</b>	<b>SESSION 1</b> <b>Epidemiology, pathology and endoscopy of gastric cancer</b>	
30'	Epidemiology (including GE junction tumours) and clinical presentation	Andrés Cervantes, ES
30'	Pathology and carcinogenesis	Fatima Carneiro, PT
30'	Endoscopy in gastric cancer: New imaging techniques, new treatment modalities (EMR, ESD)	Fabrice Caillol, FR
15'	Discussion	Faculty
<b>10:55-11:30</b>	<b>Coffee break</b>	
<b>11:30-13:00</b> <b>90'</b>	<b>SESSION 2</b> <b>Surgical, adjuvant and neoadjuvant treatment of gastric cancer</b>	
30'	Surgery for gastric and GE junction cancer, primary, palliative - where and when?	William Allum, UK
25'	Neo- and adjuvant treatment for gastric cancer and GE junction cancer: The role of radiotherapy	Karin Haustermans, BE
25'	Neo- and adjuvant treatment for gastric cancer: The role of chemotherapy	Elizabeth Smyth, UK
10'	Discussion	Faculty
<b>13:00-14:00</b>	<b>Lunch</b>	
<b>14:00-15:10</b> <b>70'</b>	<b>SESSION 3</b> <b>Clinical discussions</b>	
60'	- Molecular events and classification in gastric cancer - Hereditary gastric cancer	Fatima Carneiro, PT
10'	Discussion	Faculty
<b>15:10-15:30</b>	<b>Coffee break</b>	
<b>15:30-17:30</b> <b>120'</b>	<b>SESSION 4</b> <b>Advanced disease</b>	
30'	Chemotherapy for metastatic disease	Elizabeth Smyth, UK
40'	Biological targeted agents (including HER2, EGFR, angiogenesis)	Florian Lordick, DE
40'	New targets (including cMET, FGF, mTOR, PDL, ...)	Andrés Cervantes, ES
10'	Discussion	Faculty
<b>20:30</b>	<b>Dinner</b>	

## Saturday, 7 October 2017

<b>09:00-10:45</b> <b>105'</b>	<b>SESSION 5</b> <b>Case discussion based on ESMO Clinical Practice Guidelines I</b>	
7x15'	7 x Participants clinical case discussion	Faculty
10:45-11:15	Coffee break	
<b>11:15-12:15</b> <b>60'</b>	<b>SESSION 6</b> <b>Case discussion based on ESMO Clinical Practice Guidelines II</b>	
4x15'	4 x Participants clinical case discussion	Faculty
<b>12:15-12:30</b> <b>15'</b>	<b>Future outlook, conclusion and farewell</b>	<b>Andrés Cervantes, ES</b>
12:30-13:30	Lunch	

**Note:** Each 15-minute slot for clinical case discussion includes 7' case presentation and 8' Q&A / panel discussion